CAK

CAK
Name	CAK
Organism	Homo sapiens
Uniprot	P50613
Gene	CDK7
Other names	CDK-activating kinase

CAK is a multisubunit protein kinase complex centered on the cyclin-dependent kinase CDK7 that functions as a pivotal activator of cell-cycle CDKs and as a component of the transcription factor IIH machinery. It links cell-cycle control and transcriptional regulation through phosphorylation of regulatory targets and participates in signaling pathways connected to TP53, RB1, MYC, E2F1 and other proliferative regulators. CAK activity has been characterized in organisms ranging from Saccharomyces cerevisiae to Homo sapiens and has been implicated in diverse processes studied in model systems such as Drosophila melanogaster and Mus musculus.

Definition and Overview

CAK denotes a kinase complex whose catalytic subunit is encoded by the CDK7 gene in mammals and by homologs such as Kin28 in Saccharomyces cerevisiae and Crk7 in Schizosaccharomyces pombe. The canonical complex in metazoans includes CDK7, Cyclin H (encoded by CCNH), and MAT1 (encoded by MNAT1), forming a heterotrimer analogous to complexes studied alongside CDK1, CDK2, CDK4, CDK6, and their cyclin partners. CAK functions both as a CDK-activating kinase that phosphorylates the T-loop of CDKs and as a CAK submodule within the general transcription factor complex TFIIH, which also contains subunits such as XPB and XPD and links to pathways involving NER factors like XPA and ERCC1.

History and Development

The identification of CAK emerged from biochemical fractionation studies that sought factors required for activation of CDK1 and CDK2 during the cell cycle, following foundational work on Wee1, Cdc25, and the discovery of cyclins in Xenopus laevis oocyte systems. Subsequent purification of CAK in vertebrate extracts and cloning of CDK7, CCNH, and MNAT1 genes connected CAK to TFIIH identified in studies of transcription initiation by RNA polymerase II and to DNA repair defects underlying disorders such as Xeroderma pigmentosum. Comparative genetics traced CAK homologs in yeast kinases such as Kin28, linking early yeast genetics from Lee Hartwell and Leland Hartwell to later molecular mapping in mammalian systems.

Biological Role and Mechanism

CAK activates cell-cycle CDKs by phosphorylating a conserved threonine residue in the activation segment (T-loop) of substrates including CDK1, CDK2, CDK4, and CDK6, thereby promoting cell-cycle transitions controlled by complexes with cyclins such as Cyclin A2, Cyclin B1, Cyclin D1, and Cyclin E1. As part of TFIIH, CAK phosphorylates the C-terminal domain (CTD) of the largest subunit of RNA polymerase II (RBP1), facilitating promoter escape and transitions into productive elongation in concert with factors like TFIIB, TFIIF, and elongation regulators including P-TEFb and NELF. CAK-mediated phosphorylation events intersect with signaling by mitogens through receptors such as EGFR, FGFR1, and downstream kinases including MAPK1 and AKT1.

Structure and Regulation

The CAK heterotrimer comprises CDK7, Cyclin H, and MAT1; crystal structures of the CDK7–Cyclin H core reveal similarities to other CDK–cyclin dimers such as CDK2–Cyclin A while MAT1 stabilizes the assembly and connects CAK to TFIIH subunits XPB and XPD. CDK7 activation requires phosphorylation of its own T-loop by CAK-related mechanisms and association with Cyclin H; regulatory inputs include post-translational modifications by kinases like CHK1 and ubiquitin ligases including complexes with MDM2 interactions in DDR contexts. Subcellular localization is influenced by interactions with TFIIH and components of the transcriptional preinitiation complex studied alongside Mediator.

Clinical Significance and Disorders

Aberrant CAK function contributes to uncontrolled proliferation in cancers characterized by dysregulation of TP53, RB1, or amplification of oncogenes such as MYC and ERBB2. Mutations in TFIIH subunits and perturbation of CAK activity are implicated in rare syndromes including Xeroderma pigmentosum, Cockayne syndrome, and Trichothiodystrophy, where defects in nucleotide excision repair and transcription-coupled repair produce neurodevelopmental and photosensitivity phenotypes. CAK modulation affects sensitivity to chemotherapeutics targeting Topoisomerase II and DNA damage response agents like Cisplatin and PARP inhibitors.

Research Methods and Experimental Findings

Functional dissection of CAK uses in vitro kinase assays, co-immunoprecipitation, mass spectrometry phosphoproteomics, cryo-electron microscopy of TFIIH assemblies, and genetic models including conditional knockout mice and RNA interference screens in human cell lines such as HeLa, HEK293, and U2OS. Chemical biology approaches employ small-molecule inhibitors and covalent probes; landmark studies using inhibitors such as THZ1 revealed CAK dependence in transcriptionally addicted cancers including T-cell acute lymphoblastic leukemia and small cell lung carcinoma, while structural cryo-EM studies mapped CAK integration into TFIIH alongside XPB/XPD.

Therapeutic and Biotechnological Applications

Pharmacological targeting of CAK with selective inhibitors has progressed toward oncology applications, aiming to exploit vulnerabilities in tumors driven by transcription factors like MYCN and aberrant cell-cycle control in cancers such as breast cancer and neuroblastoma. CAK modulation is explored in combination regimens with DNA-damaging agents and checkpoint inhibitors including PD-1 axis therapies to enhance tumor cytotoxicity. In biotechnology, engineered variants of CDK7 and Cyclin H are used in cell-free transcription systems and synthetic biology platforms to control phosphorylation-dependent switches modeled after regulatory modules from Saccharomyces cerevisiae and metazoan TFIIH.

Category:Protein complexes Category:Kinases Category:Transcription factors